{"id":"tnx-103","safety":{"commonSideEffects":[{"rate":null,"effect":"Reduced ejection fraction"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Dizziness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"TNX-103 selectively inhibits cardiac myosin, the motor protein responsible for heart muscle contraction. By reducing contractility in a controlled manner, it decreases cardiac workload and oxygen demand while improving diastolic function. This mechanism is intended to provide symptomatic relief and improve exercise tolerance in patients with heart failure.","oneSentence":"TNX-103 is a cardiac myosin inhibitor that reduces the force of heart muscle contraction to improve cardiac function in heart failure patients.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:39:11.213Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Heart failure with preserved ejection fraction (HFpEF)"}]},"trialDetails":[{"nctId":"NCT07436689","phase":"PHASE3","title":"Long-Term Open-Label Extension Study of Oral Levosimendan","status":"ENROLLING_BY_INVITATION","sponsor":"Tenax Therapeutics, Inc.","startDate":"2026-03-13","conditions":"Pulmonary Hypertension Associated With HFpEF","enrollment":800},{"nctId":"NCT07288398","phase":"PHASE3","title":"LEVEL-2: LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF-2","status":"RECRUITING","sponsor":"Tenax Therapeutics, Inc.","startDate":"2026-03-03","conditions":"Pulmonary Hypertension Associated With HFpEF","enrollment":540},{"nctId":"NCT05983250","phase":"PHASE3","title":"LEVosimendan to Improve Exercise Limitation in Patients With PH-HFpEF","status":"RECRUITING","sponsor":"Tenax Therapeutics, Inc.","startDate":"2024-01-10","conditions":"Pulmonary Hypertension","enrollment":230}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"TNX-103","genericName":"TNX-103","companyName":"Tenax Therapeutics, Inc.","companyId":"tenax-therapeutics-inc","modality":"Small molecule","firstApprovalDate":"","aiSummary":"TNX-103 is a cardiac myosin inhibitor that reduces the force of heart muscle contraction to improve cardiac function in heart failure patients. Used for Heart failure with preserved ejection fraction (HFpEF).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}